Atara partner Pierre Fabre resubmits tabelecleucel BLA to FDA
Atara said it expects a revised PDUFA date once the FDA sets the review timeline. Approval would trigger a $31 million milestone payment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Atara Biotherapeutics, Inc. (ATRA) Partner Resubmits Tab-cel BLA to FDA
Atara said partner Pierre Fabre resubmitted the tabelecleucel (tab-cel) BLA to the FDA with additional patients and longer follow-up from the ALLELE study. Atara expects to provide a revised anticipated PDUFA date when available.Material DetailsContext by AI AnalystThis is a regulatory re-filing st…